Valuation: ProMIS Neurosciences, Inc.

Market Cap 135M 95.51M 84M 79.43M 72.04M 9.17B 136M 951M 367M 4.68B 359M 351M 15.03B P/E 2026 *
-2.09x
P/E 2027 * -2.7x
Enterprise Value 135M 95.51M 84M 79.43M 72.04M 9.17B 136M 951M 367M 4.68B 359M 351M 15.03B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
88.13%
Yield 2026 *
-
Yield 2027 * -
1 day-5.50%
1 week-23.98%
Current month-18.52%
1 month-23.87%
3 months+1.14%
6 months-27.75%
Current year+56.04%
1 week 10.51
Extreme 10.51
14.22
1 month 10.51
Extreme 10.51
14.96
Current year 6.72
Extreme 6.72
27.4
1 year 6.27
Extreme 6.27
27.4
3 years 6.27
Extreme 6.27
77.5
5 years 6.27
Extreme 6.27
245
10 years 6.27
Extreme 6.27
1,050
Manager TitleAgeSince
Chief Executive Officer 63 2023-12-29
Chief Tech/Sci/R&D Officer 74 2004-05-30
Director of Finance/CFO 69 2017-03-21
Director TitleAgeSince
Chairman 74 2012-10-02
Chairman 88 2014-06-11
Chairman 66 2015-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/5/26 Buy

Executive/Senior Manager

2,280 0.0254%
5/20/26 Free

Principal Accounting Officer

18,167 0.2026%
5/20/26 Free

Executive/Senior Manager

50,000 0.5576%
Change 5-day change 1-year change 3-year change Capi.($)
-5.50%-23.98%+4.21%-78.15% 101M
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-3.08%+37.74%+84.21% 60.24B
+0.75%+6.06%+36.71%+19.87% 27.73B
-0.14%-1.94%-14.13%+354.32% 25.73B
+0.57%+3.14%+1.02%-3.92% 24.75B
+1.10%+1.86%+25.07%-8.51% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.36%+0.02%+49.51%+163.05% 14.41B
-2.53%-1.39%-6.38%+469.36% 14.23B
Average -0.75%-2.08%+34.12%+140.79% 27.53B
Weighted average by Cap. -0.12%-1.06%+38.12%+125.21%

Financials

2026 *2027 *
Net sales - -
Net income -63.8M -45.03M -39.61M -37.45M -33.97M -4.32B -64.17M -448M -173M -2.21B -169M -165M -7.09B -75.26M -53.13M -46.72M -44.18M -40.08M -5.1B -75.7M -529M -204M -2.6B -199M -195M -8.36B
Net Debt - -
Logo ProMIS Neurosciences, Inc.
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Employees
11
Date Price Change Volume
26-09-28 US$10.65 -5.50% 25,055
26-09-25 US$11.27 -2.59% 20,104
26-09-24 US$11.57 -10.59% 52,696
26-09-23 US$12.94 -4.71% 43,687
26-09-22 US$13.58 -0.37% 94,201
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
15.09CAD
Average target price
60.61CAD
Spread / Average Target
+301.71%

Quarterly revenue - Rate of surprise